Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma

被引:24
|
作者
Tarasova, V. D. [1 ]
Tuttle, R. M. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Serv Endocrinol, 1275 York Ave, New York, NY 10021 USA
关键词
Low risk thyroid cancer; papillary microcarcinoma; staging; BRAF V600E MUTATION; ACTIVE SURVEILLANCE; RADIOACTIVE IODINE; CARCINOMA; ASSOCIATION; RECURRENCE; STRATIFICATION; SURGERY; PROGNOSIS; IMPACT;
D O I
10.1016/j.clon.2016.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Each year, the proportion of thyroid cancer patients presenting with low risk disease is increasing. Moreover, the definition of low risk thyroid cancer is expanding and several histological subtypes beyond papillary microcarcinomas are now classified as low risk disease. This shift in the landscape of thyroid cancer presentation is forcing clinicians to critically re-evaluate whether or not traditional management paradigms that were effective in treating intermediate and high risk disease are applicable to these low risk patients. Here we review the definition of low risk disease, examine the various histological subtypes that are considered low risk in the 2015 American Thyroid Association guidelines for the management of thyroid nodules and thyroid cancer, and review our current approach to the management of these low risk tumours. (C) 2016 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:290 / 297
页数:8
相关论文
共 50 条
  • [21] Papillary thyroid microcarcinoma: optimal management versus overtreatment
    Walgama, Evan
    Sacks, Wendy L.
    Ho, Allen S.
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (01) : 1 - 6
  • [22] Current practice in intermediate risk differentiated thyroid cancer - a review
    Padovani, Rosalia do Prado
    Duarte, Fernanda Barbosa
    Nascimento, Camila
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2024, 25 (01) : 95 - 108
  • [23] Active surveillance of low-risk papillary thyroid microcarcinomas
    Ito, Yasuhiro
    Miyauchi, Akira
    GLAND SURGERY, 2020, 9 (05) : 1663 - 1673
  • [24] Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study
    Nickel, Brooke
    Brito, Juan P.
    Barratt, Alexandra
    Jordan, Susan
    Moynihan, Ray
    McCaffery, Kirsten
    THYROID, 2017, 27 (05) : 661 - 671
  • [25] BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma
    Kim, Kyeong J.
    Kim, Sin G.
    Tan, Jie
    Shen, Xiaopei
    Viola, David
    Elisei, Rossella
    Puxeddu, Efisio
    Fugazzola, Laura
    Colombo, Carla
    Jarzab, Barbara
    Czarniecka, Agnieszka
    Lam, Alfred K.
    Mian, Caterina
    Vianello, Federica
    Yip, Linwah
    Riesco-Eizaguirre, Garcilaso
    Santisteban, Pilar
    O'Neill, Christine J.
    Sywak, Mark S.
    Clifton-Bligh, Roderick
    Bendlova, Bela
    Sykorova, Vlasta
    Xing, Mingzhao
    EUROPEAN JOURNAL OF CANCER, 2020, 124 : 161 - 169
  • [26] Nonoperative management of low-risk differentiated thyroid carcinoma
    Ito, Yasuhiro
    Miyauchi, Akira
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (01) : 15 - 20
  • [27] Active surveillance is an excellent management technique for identifying patients with progressive low- risk papillary thyroid microcarcinoma requiring surgical treatment
    Fujishima, Makoto
    Miyauchi, Akira
    Ito, Yasuhiro
    Kudo, Takumi
    Noda, Takuya
    Sano, Tsutomu
    Sasaki, Takahiro
    Kishi, Taketoshi
    Nakamura, Tomohiko
    ENDOCRINE JOURNAL, 2023, 70 (04) : 411 - 418
  • [28] BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
    Xing, Mingzhao
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (04) : 801 - 803
  • [29] Active Surveillance for Low-Risk Differentiated Thyroid Cancer
    Ahmadi, Sara
    Alexander, Erik K.
    ENDOCRINE PRACTICE, 2023, 29 (02) : 148 - 153
  • [30] An update on the management of low-risk differentiated thyroid cancer
    Lamartina, Livia
    Leboulleux, Sophie
    Terroir, Marie
    Hartl, Dana
    Schlumberger, Martin
    ENDOCRINE-RELATED CANCER, 2019, 26 (11) : R597 - R610